Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: www.ginasthma.org. Accessed November 24, 2022.
   Google Scholar
• Hekking PPW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Bleecker ER, Bourdin A, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401–413. doi:10.2147/JAA.S227170
   PubMed Web of Science ®Google Scholar
• Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381–4392.e4. doi:10.1016/j.jaip.2021.07.058
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006
   PubMed Web of Science ®Google Scholar
• Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission- what is it and how can it be achieved? Eur Respir J. 2022;60:2102583. doi:10.1183/13993003.02583-2021
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69(4):519–548. doi:10.1016/j.alit.2020.08.001
   PubMed Web of Science ®Google Scholar
• Numata T, Nakayama K, Utsumi H, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med. 2019;19:176. doi:10.1186/s12890-019-0952-1
   PubMed Web of Science ®Google Scholar
• Numata T, Miyagawa H, Nishioka S, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulm Med. 2020;20(1):207. doi:10.1186/s12890-020-01248-x
   PubMed Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allergy. 2021;14:609–618. doi:10.2147/JAA.S311975
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751. doi:10.1016/j.jaci.2018.09.033
   PubMed Web of Science ®Google Scholar
• Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124(4):719–723. doi:10.1016/j.jaci.2009.06.053
   PubMed Web of Science ®Google Scholar
• D’Ancona G, Kavanagh JE, Dhariwal J, et al. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma. Allergy. 2021;76(7):2238–2241. doi:10.1111/all.14737
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083
   PubMed Web of Science ®Google Scholar
• Drick N, Milger K, Seeliger B, et al. Switch from il-5 to il-5-receptor α antibody treatment in severe eosinophilic asthma. J Asthma Allergy. 2020;13:605–614. doi:10.2147/JAA.S270298
   PubMed Web of Science ®Google Scholar
• Gómez-Bastero Fernández A, Medina Gallardo JF, Delgado Romero J, et al. Effectiveness of switching to benralizumab in severe refractory eosinophilic asthma. J Asthma Allergy. 2022;15:727–735. doi:10.2147/jaa.s358705
   PubMed Web of Science ®Google Scholar
• Corren J, Silver J, Molfino NA, et al. A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab. Ann Allergy Asthma Immunol. 2022;128(2):184–192.e1. doi:10.1016/j.anai.2021.11.005
   PubMed Web of Science ®Google Scholar
• Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177–1185.e4. doi:10.1016/j.jaip.2020.09.014
   PubMedGoogle Scholar
• Hamada S, Ogino E, Yasuba H. Cycling biologic therapy for severe asthma: cycling therapy. Pulmonology. 2022;28(1):65–67. doi:10.1016/j.pulmoe.2021.07.009
   PubMed Web of Science ®Google Scholar
• Hamada S, Ogino E, Yasuba H. Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media. Allergol Int. 2021;70(3):389–391. doi:10.1016/j.alit.2021.02.002
   PubMed Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Real-world effectiveness of dupilumab for patients with severe asthma: a retrospective study. J Asthma Allergy. 2022;15:395–405. doi:10.2147/JAA.S357548
   PubMed Web of Science ®Google Scholar
• Motomura Y, Morita H, Moro K, et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity. 2014;40(5):758–771. doi:10.1016/j.immuni.2014.04.013
   PubMed Web of Science ®Google Scholar
• Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17(7):765–774. doi:10.1038/ni.3489
   PubMed Web of Science ®Google Scholar
• Winter NA, Qin L, Gibson PG, et al. Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma. J Allergy Clin Immunol. 2021;148(2):428–438. doi:10.1016/j.jaci.2021.01.033
   PubMed Web of Science ®Google Scholar
• Ono E, Taniguchi M, Higashi N, et al. CD203c expression on human basophils is associated with asthma exacerbation. J Allergy Clin Immunol. 2010;125(2):483–489.e3. doi:10.1016/j.jaci.2009.10.074
   PubMed Web of Science ®Google Scholar
• Lewis SA, Pavord ID, Stringer JR, Knox AJ, Weiss ST, Britton JR. The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults. Chest. 2001;119(1):105–114. doi:10.1378/chest.119.1.105
   PubMed Web of Science ®Google Scholar
• Wu X, Wang C, Li H, et al. Circulating white blood cells and lung function impairment: the observational studies and Mendelian randomization analysis. Ann Med. 2021;53(1):1118–1128. doi:10.1080/07853890.2021.1948603
   PubMed Web of Science ®Google Scholar
• Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol. 2007;19(6):676–680. doi:10.1016/j.coi.2007.07.017
   PubMed Web of Science ®Google Scholar
• Doherty TA, Broide DH. Airway innate lymphoid cells in the induction and regulation of allergy. Allergol Int. 2019;68(1):9–167. doi:10.1016/j.alit.2018.11.001
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Marchewski H, Schwefel G, Stoll P, Virchow JC, Bratke K. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin Exp Allergy. 2020;50(11):1267–1269. doi:10.1111/cea.13720
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Hirano T, Oka A, Ito K, Edakuni N. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int. 2016;65(3):266–271. doi:10.1016/j.alit.2015.12.006
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, D’Ancona G, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096.e1. doi:10.1016/j.jaip.2021.01.008
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2021;2600(21):1–12. doi:10.1016/s2213-2600(21)00352-0
   Google Scholar
• Wenzel EHB, Thompson S, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.e1. doi:10.1016/j.clinthera.2016.07.010
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi:10.1016/S2213-2600(17)30344-2
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080. doi:10.1016/j.rmed.2020.106080
   PubMed Web of Science ®Google Scholar
• Abe K, Miyawaki A, Nakamura M, Ninomiya H, Kobayashi Y. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. J Allergy Clin Immunol Pract. 2021;9(1):494–496.e1. doi:10.1016/j.jaip.2020.09.060
   PubMed Web of Science ®Google Scholar
• Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal masking in hospitals in the covid-19 era. N Engl J Med. 2020;382(21):e63. doi:10.1056/NEJMp2006372
   PubMed Web of Science ®Google Scholar